Caris Life Sciences Selects Illumina’s MiSeq® System to Enable Next-Generation Sequencing as Part of its Molecular Profiling

  Caris Life Sciences Selects Illumina’s MiSeq® System to Enable
  Next-Generation Sequencing as Part of its Molecular Profiling Service

 Collaboration Enhances Breadth and Depth of Therapeutic Information to Help
               Oncologists Better Personalize Cancer Treatment

Business Wire

SAN DIEGO -- November 07, 2012

Illumina, Inc. (NASDAQ:ILMN) today announced that Caris Life Sciences has
selected its MiSeq sequencing system to support Caris’ evidence-based
molecular profiling service. The MiSeq system will be deployed to
enablerapid, simultaneous analysis of multiple genes from formalin-fixed,
paraffin-embedded (FFPE) tumor tissues using Illumina’s amplicon-based assay.

Caris Life Sciences’ molecular profiling service offers comprehensive tumor
biomarker analyses coupled with an extensive clinical literature review, which
matches potential therapies to patient-specific biomarker information. Using a
wide array of the most clinically relevant technologies available, this
service continually evolves with the emerging science to help oncologists
personalize care for cancer patients. The addition of next-generation
sequencing to Caris’ molecular profiling service represents the next step in
the natural evolution of this cutting-edge offering.

“We are pleased to be the selected sequencing platform for Caris Life
Sciences, an unmatched leader in tumor profiling, whose molecular profiling
service has been ordered for more than 40,000 patients to date,” said Matt
Posard, Senior Vice President and General Manager of Illumina’s Translational
and Consumer Genomics business. “This collaboration is an excellent example of
applying next-generation sequencing with the goal of improving patient
outcomes.”

Caris Life Sciences is one of the few entities to offer next-generation
sequencing commercially in their CLIA-accredited laboratory, and will replace
its current sequencing technology with Illumina’s MiSeq system. The addition
of next-generation sequencing via the MiSeq complements the variety of highly
integrated technology platforms already employed by Caris, including
immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and
polymerase chain reaction (PCR). Caris’ molecular profiling service uses these
cutting-edge technologies to comprehensively interrogate the entire cancer
biological process — including DNA, RNA, and protein analysis.

“Caris leverages the most clinically relevant technologies and biomarkers to
help physicians individualize care. When we choose to add a new technology to
our portfolio, we are committed to selecting a best-in-class platform and
partner, as evidenced by our selection of Illumina,” said Tom Spalding, Senior
Vice President, Group Head Oncology and Chief Marketing Officer at Caris Life
Sciences. “After a thorough evaluation of top NGS platforms, Illumina’s data
quality, simple workflow, and commitment to a collaborative approach were key
to our decision to work with them.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

About Caris Life Sciences

Caris Life Sciences is a leading biosciences company focused on developing and
delivering innovative molecular diagnostic, prognostic, and theranostic
services. The company’s evidence-based molecular profiling service matches
molecular data generated from a patient’s tumor with biomarker/drug
associations derived from the world’s leading clinical cancer literature. This
service uses the most advanced and clinically relevant technologies to provide
physicians with information to aid in the selection of personalized cancer
treatments more likely to work for each patient. Caris is also developing a
series of blood tests based on the company’s proprietary Carisome™ platform —
a proprietary, blood-based testing technology for diagnosis, prognosis, and
theranosis of cancer and other complex diseases. Through the precise and
personalized information provided by technologies like molecular profiling and
Carisome, the company believes that the quality of healthcare can be
dramatically improved, while also significantly reducing costs. Headquartered
in the Dallas metroplex, Caris Life Sciences offers services throughout the
United States, Europe, and other international markets. To learn more, please
visit www.carislifesciences.com.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.